The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion reported that the recently released 52-week results from its Phase II COVALENT-112 trial evaluating icovamenib in type 2 diabetes revealed increased C-peptide secretion.
Dr. G. Alexander Zan Fleming, MD, a former FDA senior medical officer and a recognized leader in diabetes drug development, presented these findings, indicating a potentially significant advance in diabetes treatment research. The focus on C-peptide secretion highlights the trial's emphasis on pancreatic beta-cell function, a crucial marker for therapeutic efficacy in diabetes management.
Biomea Fusion previously reported that diabetes remains poorly controlled in many patients, pointing to ongoing unmet needs in current therapies (read more). The company also recently launched enrollment for its COVALENT-212 clinical trial evaluating icovamenib in type 2 diabetes patients (read more). These efforts reflect Biomea Fusion’s continuing focus on advancing diabetes treatment options.